American Society of Hirudotherapy

Leech Phospholipase A2 Inhibitor

Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Leech Phospholipase A2 Inhibitor15 kDa
Molecular weight (kilodaltons) of Leech Phospholipase A2 Inhibitor (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

This PLA2 inhibitor is hypothesized only. Sequence-level cataloging does NOT establish anti-inflammatory clinical efficacy. No FDA-approved derivative exists.

Molecular Profile

Category
Anti-inflammatory
Evidence tier
Preclinical
Molecular weight
15,000 Da
Source species
Hirudo medicinalis
Discovered
2018

Biological Targets

  • → secretory phospholipase A2 (predicted)

External Resources

    Related Anti-inflammatory Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.